Entera Bio

Entera Bio Free Cash Flow

The Free Cash Flow (FCF) of Entera Bio (ENTX) as of Nov 22, 2026 is -7.48 M USD. In the previous year, Free Cash Flow (FCF) was -6.82 M USD — a change of 9.62% (lower).

Free Cash Flow

-7.48 MUSD

YoY

9.62%

Last updated:

Free Cash Flow (FCF) of Entera Bio is 2025 -7.48 M USD. Free Cash Flow (FCF) of Entera Bio was 2024 -6.82 M USD. It decreases by 9.62% lower compared to the previous year.

The Entera Bio Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
-9.86 M USD
Jan 1, 2019
-8.96 M USD
Jan 1, 2020
-10.61 M USD
Jan 1, 2021
-9.08 M USD
Jan 1, 2022
-12.55 M USD
Jan 1, 2023
-7.33 M USD
Jan 1, 2024
-6.82 M USD
Jan 1, 2025
-7.48 M USD
The Entera Bio Free Cash Flow history
YEARFree Cash FlowYoY
-7.48 MUSD+9.62%
-6.82 MUSD-6.91%
-7.33 MUSD-41.60%
-12.55 MUSD+38.17%
-9.08 MUSD-14.42%
-10.61 MUSD+18.43%
-8.96 MUSD-9.17%
-9.86 MUSD+115.51%
-4.58 MUSD+43.80%
-3.18 MUSD-10.31%
-3.55 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Free Cash Flow (FCF) of Entera Bio is -7.48 M USD in 2025.

Free Cash Flow (FCF) of Entera Bio changed from -6.82 M USD to -7.48 M USD, representing a 9.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Entera Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Entera Bio

All Key Metrics — Entera Bio